Theriva Biologics, Inc. (TOVX) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings. Welcome to Cereva Biologics 2022 Full Year Operational Highlights and Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Chris Calabrese with LifeSci Advisors. Thank you. You may begin. Thank you, Operator, and good morning, everyone. Welcome to Cereva Biologics' full year 2022 investor conference call. Leading the call today will be Stephen Shawcross, Chief Executive and Chief Financial Officer of Cereva Biologics. Dr. Manel Cascaio, General Director of Cereva Biologics, European subsidiary, Dr. Frank Tufaro, Chief Operating Officer, and Dr. Vince Wacher, Head of Corporate and Product Development of Cereva Biologics, are also on the call and will be available to answer questions during the Q&A session. Theriva Biologics issued a press release this morning, which provided operational highlights and included the financial results for the full year ending December 31st, 2022. The press release can be found in the investor section of the company website at www.therivabio.com, together with the annual report on Form 10-K for year ended December 31st, 2022, which we plan to file today with the Securities and Exchange Commissioner, SEC. In addition to the phone line, this call is being streamed live via webcast, which will be archived on the company website, www.cerevabio.com, for 90 days. During this call, certain forward-looking statements regarding Cereva Biologics and VCN Biosciences' current expectations and projections about future events will be mad...